, Volume 8, Issue 1, pp 69–83 | Cite as

Semi-synthesis of polymyxin-B conjugated ovalbumin: Evaluation of lipopolysaccharide binding avidity and neutralization of induced tnf-α synthesis

  • C. P. Coyne
  • J. T. Moritz
  • V. Cory Langston


A method is described in these investigations for the semi-synthetic production of polymyxin-B conjugated ovalbumin in the form of polymyxin-B·Sulfo-SMCC·ovalbumin (PSO). The heterobifunctional “cross-linking” agent, Sulfo-SMCC was first reacted with polymyxin-B to produce a relatively pure reactive intermediate in the form of polymyxin-B·Sulfo-SMCC. Highly purified ovalbumin was then combined with the polymyxin-B·Sulfo-SMCC reactive intermediate and contaminants removed from the final PSO end product by exhaustive microdialysis. Purity of PSO was established with by high-performance cellulose acetate electrophoresis (HPCAE), and high-performance thin layer chromatography (HPTLC) analyses. Verification of polymyxin-B·Sulfo-SMCC·ovalbumin binding avidity for lipopolysaccharide (LPS) was determined by DotBlot analysis applying fluorescein isothiocyanate labeledE. coli (055:B5) LPS fractions (FITC-LPS). Efficacy of PSO to inhibitin vitro LPS-induced synthesis of tumor necrosis factor-alpha (TNF-α) was assessed with a tissue culture based biological assay system. In this context, semi-synthetic conjugates of PSO (0.349μg/ml) effectively inhibitedSalmonella minnesota (RS) LPS (2.5 ng/ml well) induced TNF-a synthesis and corresponding cytoprotection (100%) to WEHI 164 clone 13 cell populations.

Key words

Polymyxin B lipid A-core lipopoly saccharide LPS TNF-α HPTLC HPCAE 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Shenep JL, Barton RP, Morgan KA. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1985; 151: 1012–1018.PubMedGoogle Scholar
  2. 2.
    Shenep JL, Morgan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 1984; 150: 380–388.PubMedGoogle Scholar
  3. 3.
    Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 1988; 157: 565–568.PubMedGoogle Scholar
  4. 4.
    Dunn DL, Mach PA, Condie RM, Cerra FB. Anticore endotoxin F(ab′)2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis. Surg 1984; 96: 440–446.Google Scholar
  5. 5.
    Dunn DL, Bogard WC, Cerra FB. Efficacy of type-specific and cross reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis. Surg 1985; 98: 283–290.Google Scholar
  6. 6.
    Adhikari M, Coovadia HM, Gaffin SL, Brock-Utne JG, Marivate M, Pudifin DJ. Septicaemic low birthweight neonates treated with human antibodies to endotoxin. Arch Dis Child 1985; 60: 382–384.PubMedGoogle Scholar
  7. 7.
    Morre JN. Endotoxin-induced procoagulant activity, eicosanoid synthesis, and tumor necrosis factor production by rat peritoneal macrophages: effect of endotoxin tolerance and glucan. Circ Shock 1990; 31: 281–295.PubMedGoogle Scholar
  8. 8.
    Garner HE, Sprouse RF, Lager K. Cross protection of ponies from sublethalEscherichia coli endotoxemia bySalmonella typhimurium antiserum. Eq Pract 1988; 10: 10–16.Google Scholar
  9. 9.
    Gaffin SL. Gram-negative bacteraemia: New therapeutic possibilities with anti-endotoxin antibodies. Haematol Blood Trans 1985; 29: 107–111.Google Scholar
  10. 10.
    Remick DG, Strieter RM, Lynch JP, Nguyen D, Eskandari M, Kunkel SL.In vivo dynamics of murine tumor necrosis factoralpha gene expression: kinetics of dexamethazone-induced suppression. Lab Invest 1991.Google Scholar
  11. 11.
    Spengler RN, Spengler ML, Strieter RM, Remick DG, Larrick JW, Kunkel SL. Modulation of tumor necrosis factor-alpha gene expression: desensitization of prostaglandin E2-induced suppression. J Immunol 1989; 142: 4346–4350.PubMedGoogle Scholar
  12. 12.
    Goto F, Watanabe E, Maruyama N. Prevention of the toxic action of tumor necrosis factor by cyclooxygenase inhibitor and leukopenia. Circ Shock 1989; 29: 175–180.PubMedGoogle Scholar
  13. 13.
    White C, Ghezzi P. Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: Role of antioxidant enzymes and effect of cyclooxygenase inhibitors. Biotherapy 1989; 1: 361–367.PubMedGoogle Scholar
  14. 14.
    Evans DA, Jacobs DO, Revhaug A. The effects of tumor necrosis factor and their selective inhibition by ibuprofen. Ann Surg 1989; 1: 312–321.Google Scholar
  15. 15.
    Schade UF, Ernst M, Reinke M. Lipoxygenase inhibitors suppress formation of tumor necrosis factorin vitro andin vivo. Biochem Biophys Res Comm 1989; 159: 748–758.PubMedGoogle Scholar
  16. 16.
    Sheehan KCF, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989; 142: 3884–3893.PubMedGoogle Scholar
  17. 17.
    Sherry BA, Gelin J, Fong Y. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J 1989; 3: 1956–1962.PubMedGoogle Scholar
  18. 18.
    Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599–607.PubMedGoogle Scholar
  19. 19.
    Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974–11980.PubMedGoogle Scholar
  20. 20.
    Seckinger P, Isaaz S, Dayer J. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chemistry 1989; 264: 11966–11973.Google Scholar
  21. 21.
    Dunn DL, Mach PA, Condie RM, Cerra FB. Anticore endotoxin F(ab′)2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial septis. Surg 1984; 96: 440–444.Google Scholar
  22. 22.
    Miner KM. Characterization of murine monoclonal antibodies toEscherichia coli J5. Infect Immun 1986; 1: 56–62.Google Scholar
  23. 23.
    Cullor, JS, Fenwick B, Smith BP, Pelzer K, Kelly A, Osbum BI. Active immunization withE. coli J5 and its protective effects from endotoxic shock in calves. In:Immunobiology and Immunopharmacology of Bacterial Endotoxins. Szentivanyi A, Friedman H, Nowotny A, eds. New York, NY: Plenum Press, 1986, p. 265–268.Google Scholar
  24. 24.
    Walterspiel JW, Kaplan SL, Mason EO. Protective effect of subinhibitory polymyxin-B alone and in combination with ampicillin for overwhelmingHaemophilus infiuenzae Type B infection in the infant rat: Evidence forin vivo andin vitro release of free endotoxin after ampicillin treatment. Ped Res 1986; 20: 237–241.Google Scholar
  25. 25.
    Bannatyne RM, Cheung R. Infection in neutropenia: Antiendotoxin effect of polymyxin. Anticancer Res 1982; 2: 239–240.PubMedGoogle Scholar
  26. 26.
    Cohen J, Pusey CD, Ryan CJ. Protection from endotoxemia: A rat model of plasmaphoresis and specific adsorption with polymyxin-B. J Infect Dis 1987; 155: 690–695.PubMedGoogle Scholar
  27. 27.
    Flynn PM, Shenep JL, Stokes DC, Fairclough D, Hildner WK. Polymyxin-B moderates acidosis and hypotension in established experimental gram-negative septicemia. J Infect Dis 1987; 156: 706–712.PubMedGoogle Scholar
  28. 28.
    Munster AM, Xiao GX, Guo Y, Wong LA, Winchurch RA. Control of endotoxemiain burn patients by use of polymyxin-B. J Burn Rehab 1989; 10: 327–330.Google Scholar
  29. 29.
    Hanasawa K. Selective removal of endotoxin from the blood by extracorporeal hemoperfusion with polymyxin B immobilized fiber. Prog Clin Biol Res 1988; 264: 337–341.PubMedGoogle Scholar
  30. 30.
    Bannatyne RM, Harnett NM, Lee KY, Biggar WD. Inhibition of the biological effects of endotoxin on neutrophils by polymyxin-B sulfate. J Infect Dis 1977; 136: 469–474.PubMedGoogle Scholar
  31. 31.
    Cooperstock M, Riegle L. Polymyxin-B inactivation of lipopolysaccharide in vaccines of gram-negative bacteria. Infect Immun 1984; 33: 315–318.Google Scholar
  32. 32.
    Corrigan JJ, Bell BM. Comparison between the polymyxins and gentamicin in preventing endotoxin-induced intravascular coagulation and leukopenia. Infect Immun 1971; 4: 563–566.PubMedGoogle Scholar
  33. 33.
    Corrigan JJ, Bell BM. Endotoxin-induced intravascular coagulation: prevention with polymyxin-B sulfate. J Lab Clin Med 1971; 77: 802–810.PubMedGoogle Scholar
  34. 34.
    Duff GW, Atkin E. The inhibitory effect of polymyxin-B on endotoxin-induced endogenous pyrogens production. J Immunol Methods 1982; 52: 333–340.PubMedGoogle Scholar
  35. 35.
    Issekutz AC, Bhimji S, Bartolussi R. Effect of immune serum or polymyxin-B onEscherichia coli-induced inflammation and vascular injury. Infect Immun 1982; 36: 548–557.PubMedGoogle Scholar
  36. 36.
    Luderitz O, Freudenberg MA, Galanos C, Lehman V, Rietschel ET, Shaw DW. Lipopolysaccharides of gramnegative bacteria. In: Current Topics in Membranes and Transport. Bronner F, Kleinzeller A, eds. NY: Academic Press, 1982, p. 79–151.Google Scholar
  37. 37.
    Sande MA, Mendell GL. Antimicrobial Agents. In: The Pharmacological Basis of Therapeutics. Gilman AG, Goodman LS, Rall TW, Murad F, eds. NY: MacMillan, 1985, p. 1191–1192.Google Scholar
  38. 38.
    Morrison DC, Jacobs DM. Binding of polymyxin-B to the lipid-A portion of bacterial lipopolysaccharides. Immunochem 1976; 13: 813–818.Google Scholar
  39. 39.
    Coyne CP, Fenwick BW. Inhibition of lipopolysaccharideinduced macrophage tumor necrosis factor-alpha synthesis by polymyxin-B sulfate. Am J Vet Res 1993; 54: 150–163.Google Scholar
  40. 40.
    Imoto M, Yshimura N, Kusumoto S. Total synthesis of lipid A, active principal of bacterial endotoxin. Proc J Acad 1984; 60: 285–290.Google Scholar
  41. 41.
    Hase S, Rietschel ET. Isolation and analysis of the lipid A backbone: Lipid A structure of lipopolysaccharides from various bacterial groups. Eur J Biochem 1973; 63: 101–107.Google Scholar
  42. 42.
    Stokes D, Shenep JL, Fishman M, Hildner WK, Bysani GK, Rufus K. Polymyxin B prevents lipopolysaccharideinduced release of tumor necrosis factor-alpha from alveolar macrophages. J Infect Dis 1989; 160: 52–57.PubMedGoogle Scholar
  43. 43.
    Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibody. Proc Natl Acad Sci 1990; 87: 3127–3131.PubMedGoogle Scholar
  44. 44.
    Hohmann HP, Remy R, Brockhaus M, van Loon APGM. Two different cell types have different major receptors for human necrosis factor (TNF-alpha). J Biol Chem 1989; 264: 14927–14934.PubMedGoogle Scholar
  45. 45.
    Hohmann HP, Remy R, Poschl B. Tumor necrosis factors-alpha and beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kB at low receptor occupancy and within minutes after receptor binding. J Biol Chem 1990; 265: 15183–15188.PubMedGoogle Scholar
  46. 46.
    Coyne CP, Fenwick BW, Iandolo J, Griffith G, Williams D. Isolation of an inhibitor of TNF-alpha from activated equine mixed white blood cell populations. Am J Vet Res 1993; 54: in press.Google Scholar
  47. 47.
    Chia JKS, Pollack M, Guelde G, Koles NL, Miller M, Evans ME. Lipopolysaccharide (LPS)-reactive monoclonalantibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse derived macrophages. J Infect Dis 1989; 159: 872–880.PubMedGoogle Scholar
  48. 48.
    Han Jf, Thompson P, Beutler B. Dexamethazone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at seperate points in the signaling pathway. J Exp Med 1990; 172: 391–394.PubMedGoogle Scholar
  49. 49.
    Taffet SM, Singhel KJ, Overholtzer JF, Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 1989; 120: 291–300.PubMedGoogle Scholar
  50. 50.
    Meager A, Leung H, Woolley J. Assays for tumour necrosis factor and related cytokines. J Immun Meth 1989; 116: 1–17.Google Scholar
  51. 51.
    Hofsli EVA, Bakke O, Nonstad U, Espevik T. A flow cytometric and immunofluoroscence microscopic study of tumor necrosis factor production and localization in human monocytes. Cell Immunol 1989; 122: 405–415.PubMedGoogle Scholar
  52. 52.
    Espevik T, Nissen-Meyer J. Application of WEHI clone 164 cell line forthe detection of TNF-alpha monokine. J Immunol 1987; 61: 443–449.Google Scholar
  53. 53.
    Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI clone 164 for measuring cytotoxicity factor/tumor necrosis factor from human monocytes. Methods 1990; 95: 99–105.Google Scholar
  54. 54.
    Lokesh BR, Sayers TJ, Kinsell JE. Interleukin-1 and tumor necrosis factor synthesis by mouse peritoneal macrophages is enhancedby dietary h-3 polyunsaturated fatty acids. Immunol Let 1990; 23: 281–286.PubMedGoogle Scholar
  55. 55.
    Eskandari MK, Nguyen DT, Kinkel SL. WEHI 164 clone 13 assay for TNF: Sensitivity, specificity and reliability. Immunol Invest 1990; 19(1): 69–79.PubMedGoogle Scholar
  56. 56.
    Nguyer DT, Eskandari MK, DeForge LE. Cyclosporin-A modulation on tumor necrosis factor gene expression and effectsin vitro andin vivo. Immunol Invest 1990; 144(10): 3822–3828.Google Scholar
  57. 57.
    Remick DG, Nguyen DT, Eskandari MK. Cyclosporin-A inhibits TNF production without decreasing TNF mRNA levels. Biochem Biophys Res Comm 1990; 161: 551–555.Google Scholar
  58. 58.
    Hori K, Mihich E, Ehrke MJ. Role of tumor necrosis factor and interleukin-1 in gamma-interferon promoted activation of mouse tumorcidal macrophages. Cancer Res 1989; 49: 2600–2614.Google Scholar
  59. 59.
    Galanos C, Luderitz O, Rietschel ET, Westphal O. Newer aspects of the chemistry and biology of bacterial lipopolysaccharides, with special reference to their lipid-A components. In: Intern Rev of Biochem Biochemistry of Lipids II, Goodwin, TW, ed. Baltimore: Univ Park Press, 1977, p. 239–335.Google Scholar
  60. 60.
    Rietschel ET, Hase S, King MT. Chemical structure of lipid A. Eur J Biochem 1976; 63: 262–268.Google Scholar
  61. 61.
    Westphal O, Gmeiner J, Luderitz O. Chemistry and biology of the lipid-A component of enterobacterial lipopolysaccharides. Colloq Int CNRS Paris 1969; 174: 69–78.Google Scholar
  62. 62.
    Rifkind D. Prevention by polymyxin-B of endotoxin lethality in mice. J Bacteriol 1967; 93: 1463–1464.PubMedGoogle Scholar
  63. 63.
    Corrigan JJ, Sieber OF, Ratajczak H, Bennet BB. Modification of human neutrophil response to endotoxin with polymyxin-B sulfate. J Infect Dis 1974; 130: 384–387.PubMedGoogle Scholar
  64. 64.
    Cooperstock MS. Inactivation of endotoxin by polymyxin-B. Antimicrob Agents Chemother 1974; 6: 422–425.PubMedGoogle Scholar
  65. 65.
    Craig WA, Turner JH, Kunin CM. Prevention of the generalized Schwartzman reaction and endotoxin lethality by polymyxin-B localized in tissues. Infect Immun 1974; 10: 287–292.PubMedGoogle Scholar
  66. 66.
    Palmer JD, Rifkind D. Neutralization of the hemodynamic effects of endotoxin by polymyxin-B. Surg Gynecol Obstet 1974; 138: 755–759.PubMedGoogle Scholar
  67. 67.
    Fong JSC, Good RA. Polymyxin-B sulfate modification of bacterial endotoxin: effects on the development of endotoxic shock in dogs. Infect Immun 1979; 23: 660–664.PubMedGoogle Scholar
  68. 68.
    Coopershock M, Riegle L. Polymyxin-B inactivation of lipopolysaccharide in vaccines of gram-negative bacteria. Infect Immun 1981; 33: 315–318.PubMedGoogle Scholar
  69. 69.
    Hughes B, Riegle L. Polymyxin-B sulfate protects cats against the haemodynamic and metabolic effects ofE. coli endotoxin. Br J Pharmacol 1981; 74: 701–707.PubMedGoogle Scholar
  70. 70.
    Rudd P, Blaschke T. Antihypertensive agents and the drug therapy of hypertension. In: The Pharmacological Basis of Therapeutics. Gillman AG, Goodman LS, Rall TW, Murad F, eds. NY: MacMillan, 1985, p. 784–805.Google Scholar
  71. 71.
    Rifkind D, Palmer JD. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol 1966; 92: 815–819.PubMedGoogle Scholar
  72. 72.
    Takayama K, Qureshi N, Raetz CRH,et al. Influence of fine structure of lipid-A on Limulus amebocyte lysate clotting and toxic activities. Infect Immun 1984; 45: 350–355.PubMedGoogle Scholar
  73. 73.
    Takayama K, Qureshi N, Ribi E, Cantrell JL, Amano K. Use of endotoxin in cancer immunotherapy and characterization of its nontoxic but active lipid-A components. In: Bacterial Lipopolysaccharides: Structure, Synthesis, and Biological Activities, Anderson L, Unger F, eds. Washington. D.C.: American Chemical Society, 1983, p. 219–233.Google Scholar
  74. 74.
    Endres vitro production of IL-1 beta, IL-2 alpha, TNF and IL-2 in healthy subjects, distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 1989; 19: 2327–2333.PubMedGoogle Scholar
  75. 75.
    Suffys P, Beyoert R, Van Roy F, Fiers W. Reduced tumor necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism. Biochem Biophys Res Commun 1987; 149: 735–743.PubMedGoogle Scholar
  76. 76.
    Fleisher LN. Time course for prostaglandin synthesis by rabbit lens during endotoxin-induced ocular inflammation. Curr Eye Res 1986; 5: 629–634.PubMedGoogle Scholar
  77. 77.
    Suttorp N. Endotoxin alters arachidonate metabolism in pulmonary endothelial cells. Am J Physiol 1987; 253: 383-C390.Google Scholar
  78. 78.
    Zia S, Giri SN, Cullor GJ, Emau P, Osburn BI, Bushnell. Role of eicosanoid, histamine, and serotonin in the pathogenisis of Klebsiella pneumonia-induced bovine mastitis. Am J Vet Res 1987; 48: 1617–1625.PubMedGoogle Scholar
  79. 79.
    Giri SN, Chen Z, Carroll EJ,et al. Role of prostaglandins in pathogenisis of bovine mastitis induced byEscherichia coli endotoxin. Am J Vet Res 1984; 45: 586–591.PubMedGoogle Scholar
  80. 80.
    Schneider J. Effects of recombinant human Superoxide dismutase on increased lung vascular permeability and respiratory disorder in endotoxic rats. Circ Shock 1990; 30: 97–106.PubMedGoogle Scholar
  81. 81.
    Recasens JF. Effects of endotoxin and anti-inflammatory agents on Superoxide dismutase in the rabbit iris. Ophthalmic Res 1990; 22: 12–18.PubMedGoogle Scholar
  82. 82.
    Cerasoli F. Superoxide anion release from blood and bone marrow neutrophils is altered by endotoxemia. Circ Res 1990; 67: 154–165.PubMedGoogle Scholar
  83. 83.
    Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Cir Shock 1990; 31: 171–181.Google Scholar
  84. 84.
    Exley AR. Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 335: 1275–1277.Google Scholar
  85. 85.
    Schollmeier K. Immunologic and pathophysiologic role of tumor necrosis factor. Am J Respir Cell Mol Biol 1990; 311: 11–12.Google Scholar
  86. 86.
    Silva AT. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Inf Dis 1990; 162: 421–427.Google Scholar
  87. 87.
    Bonavida B. The involvement of platelet-activating factor (PAF)-induced monocyte activation and tumor necrosis factor (TNF) production in shock. Prog Clin Biol Res 1989; 308: 485–489.PubMedGoogle Scholar
  88. 88.
    Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immun Immunopath 990; 1 55: 157–170.Google Scholar
  89. 89.
    Hinshaw LB, Tekamp-Olson P, Chang ACK. Survival of primates in LD-100 septic shock following therapy with antibody to tumor necrosis factor (TNF-alpha). Circ Shock 1990; 30: 279–292.PubMedGoogle Scholar
  90. 90.
    Leon P. Interleukin-1 and its relationship to endotoxin tolerance. Arch Surg 1992; 127: 146–151.PubMedGoogle Scholar
  91. 91.
    Montz H. The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunol 1991; 74: 373–379.Google Scholar
  92. 92.
    Wang MH. Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid-A partial structures in human peripheral blood mononuclear cell. Infect Immun 1991; 59: 4655–4664.PubMedGoogle Scholar
  93. 93.
    The Swiss Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991; 99: 23–29.Google Scholar
  94. 94.
    Semenzato G. Tumor necrosis factor: a cytokine with multiple biological activities. Br J Cancer 1990; 61: 354–361.PubMedGoogle Scholar
  95. 95.
    Remick DG, Strieter RM, Eskandari MK,et al. Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Amer J Path 1990; 136: 49–60.PubMedGoogle Scholar
  96. 96.
    Remick DG, Kunkel RG, Larrick JW, Kunkel SL. Acutein vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987; 56: 583–590.PubMedGoogle Scholar
  97. 97.
    Tracy KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin. Sci 1986; 470: 234–238.Google Scholar
  98. 98.
    Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925–1937.PubMedGoogle Scholar
  99. 99.
    Kawasaki H, Moriyama M, Ohtani Y, Naitoh M, Tanaka A, Nariuchi H. Analysis of endotoxin fever in rabbits by using a monoclonal antibody to tumor necrosis factor (cachectin). Infect Immun 1989; 57: 3131–3135.PubMedGoogle Scholar
  100. 100.
    Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factoralpha in experimental gram-negative shock. J Infect Dis 1990; 162: 421–427.PubMedGoogle Scholar
  101. 101.
    de Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP. Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 1989; 262: 249–251.PubMedGoogle Scholar
  102. 102.
    Sanchez-Cantu L. Endotoxin tolerance is associated with reduced secretion of tumor necrosis factor. Arch Surg 1989; 124: 1432–1435.PubMedGoogle Scholar
  103. 103.
    Poll T. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622–1627.PubMedGoogle Scholar
  104. 104.
    Myers AK. Relationships between tumor necrosis factor, eicosanoids and platelet activating factor as mediators of endotoxin-induced shock in mice. Br J Pharmacol 1990; 99: 499–502.PubMedGoogle Scholar
  105. 105.
    Flynn PM, Shenep JL, Stokes DC, Fairclough D, Hildner WK. Polymyxin-G moderates acidosis and hypotension in established, experimental gram-negative septicemia. J Infect Dis 1987; 156: 706–712.PubMedGoogle Scholar
  106. 106.
    Yow EM, Moyer JH. Toxicity of polymyxin B. II. Human studies with particular reference to evaluation of renal function. Arch Int Med 1953; 92: 248–257.Google Scholar
  107. 107.
    Danner RL, Joiner KA, Rubin M,et al. Purification, toxicity, and antiendotoxin activity of polymyxin-B nonapeptide. Antimicrob Agents Chemother 1989; 33: 1428–1434.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • C. P. Coyne
    • 1
    • 2
  • J. T. Moritz
    • 1
    • 2
  • V. Cory Langston
    • 1
    • 2
  1. 1.Veterinary Research ProgramVeterinary Pharmacology Research LaboratoryLangston
  2. 2.College of Veterinary Medicine, Wise CenterMississippi State UniversityMississippiUSA

Personalised recommendations